EyePoint Pharmaceuticals, Inc. (EYPT)
NASDAQ • Healthcare
Last close at October 23, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 4
in 10 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
EyePoint Pharmaceuticals trailed consensus on EPS but topped it on revenue in the second fiscal quarter of 2026, reported August 5, 2026, as revenue fell 90.5% to roughly $0.5 million from about $5.3 million a year ago. Revenue of $507,000.00 topped the $451,214.00 estimate, +12.4%, while EPS of -$1.09 trailed the -$1.01 estimate by -$0.08 (down from -$0.85 a year ago). With gross profit matching revenue at roughly $0.5 million, the quarter still posted an operating loss of about $97.4 million, and net income came in at a loss of roughly $94.5 million, improving 59.0% from a loss of about $59.4 million a year earlier. The company’s marketed ophthalmic portfolio includes ILUVIEN, YUTIQ, and DEXYCU. For the next period, consensus calls for EPS of -$0.91 on revenue of $232,154.00.
Next report — what to expect
EyePoint Pharmaceuticals, Inc. (EYPT) reports on November 4, 2026. Wall Street expects EPS of -$0.905 on revenue of $231,154.00. For trailing context, revenue declined -90.5% year over year last quarter. The company has beaten EPS in 0 of 8 most recent quarters.
About EyePoint Pharmaceuticals, Inc.
EyePoint Pharmaceuticals, Inc. develops and markets ophthalmic therapies for retinal and other eye disorders as a biotechnology company in healthcare. Trading on the NASDAQ Global Market as EYPT, it generates $31.4 million in FY2025 revenue from commercial eye-disease products and a pipeline aimed at chronic and sight-threatening conditions.
Today's Snapshot
EYPT closed 5.5% lower at 0.40, in line with a weaker sector. Trading was lighter than usual, with volume about two-fifths of its usual level.
Trading Volume
Below 10d avg (30.6M)
13.2M
vs S&P 500 Today
Strong Underperformance
-4.99%
Updated: October 23, 2026 at 20:18 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$1.44 - $10.00Sell
- RSI (14)15.54Buy
- Stochastic %K (14, 3, 3)1.10Buy
- MACD Level (12, 26)-1.08Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.